Arlington, VA (www.aktiencheck.de) - Rating-Update:
Mayank Mamtani, Analyst von B. Riley Securities, stuft die Aktie von Novavax Inc. (ISIN: US6700024010, WKN:…
Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80…
New Jork (www.aktiencheck.de) - Rating-Update:
Vernon Bernardino, Analyst von H.C. Wainwright & Co., bewertet die Aktie von Novavax Inc. (ISIN: US6700024010,…